InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today.

WASHINGTON, September 24, 2010 /PRNewswire/ -- InspireMD sponsored a Satellite Symposium today at the TCT conference in Washington convention center, the symposium was chaired by Drs. Alexandra J. Lansky,and Roxana Mehran. The session titled "MGuard Embolic Protection Stent: Novel Primary PCI Solutions and Challenging Cases" manifested unprecedented clinical findings of long term MGuard Multicenter Experience in STEMI (heart attack) patients, presented by Prof. Federico Piscione, from Federico-II University in Naples, Italy. Prof. Piscione presented 2 years clinical follow up of 100 patients. In an analysis of non cardiogenic shock patients (89 patients), the MACE (cardiac death, MI, TVR) rate was 7.9% (vs. 13.3% in the total group). In addition, post procedural Blush grade 3 and complete ST segment resolution were both at 90%.

"The results we obtained with the MGuard stent" commented Prof. Piscione," show that MGuard is a safe and feasible option, both at short and long-term follow-up, for STEMI patients undergoing PCI with huge thrombus burden."

Mr. Ofir Paz, InspireMD's CEO, said "We are very excited with the new clinical results of MGuard. To date, 345 STEMI patients have been enrolled in selected clinical trials to test MGuard performance in this high risk population. The outcome surpasses today's best practice, in terms of acute results as well as long term clinical follow-up. When we performed a Meta analysis of all our STEMI trials the results reveal that with MGuard it may be possible to reduce MACE by up to an astonishing 50%."

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without affecting deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

    Contact details:

    http://www.inspire-md.com
    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    [email protected]

SOURCE Inspire MD